Home / Trials and Studies/ Trial or Study

Anticoagulation in COVID pneumonia (ATTACC)

Status: Enrolment Complete

See publication: Therapeutic Anticoagulation with Heparin in Noncritically Ill Patients with Covid-19 (2021)

In noncritically ill patients with Covid-19, an initial strategy of therapeutic-dose anticoagulation with heparin increased the probability of survival to hospital discharge with reduced use of cardiovascular or respiratory organ support as compared with usual-care thromboprophylaxis.